Latest News & Features
Americas
Biopharmaceutical company Alkermes has entered into a settlement and licence agreement with generic maker Amneal Pharmaceuticals to resolve an inter partes review. 31 July 2019
Americas
In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review proceedings to a pre-American Invents Act patent isn’t unconstitutional. 31 July 2019
Big Pharma
The state of California has secured a $69 million settlement with Teva, which allegedly entered into collusive pay-for-delay agreements with generic competitors. 30 July 2019
Americas
California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit. 30 July 2019
Big Pharma
Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company. 29 July 2019
Americas
Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute. 26 July 2019
Biotechnology
One of the perennial inherent challenges for legislators and regulators is crafting laws and regulatory frameworks that are firm enough to deal with the issues of the present, but flexible enough to cater for the challenges of the future, as Daniel Lim and Anna Jackson of Kirkland & Ellis explain. 26 July 2019
Big Pharma
US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments. 25 July 2019
Big Pharma
Growth in GlaxoSmithKline’s vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair on its sales. 25 July 2019
Americas
Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology. 24 July 2019